'In transition' Shire strikes deal for follow-on Hunter syndrome product
This article was originally published in Scrip
Executive Summary
Shire is teaming up with biotechnology firm ArmaGen Technologies in order to develop an investigational enzyme replacement therapy (ERT) for the treatment of Hunter syndrome.
You may also be interested in...
Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines
Scrip spoke with Shire's Head of Genetic Diseases, Medical Affairs, Hartmann Wellhoefer about upcoming milestones in the company's R&D pipeline and improving access to medicines for rare diseases after the Baxalta merger.
WORLD Symposium Notebook: New Data In Lysosomal Diseases And A Push For Earlier Testing
The WORLD Symposium Feb. 13 to 16 in San Diego offered everything from basic research through late-stage clinical data in lysosomal diseases, including ArmaGen's blood-brain barrier-crossing treatment for Hurler syndrome and updates from ongoing development programs from rare disease specialists, such as Genzyme, Amicus and Protalix.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.